Metabolic dysfunction-associated steatotic liver disease: when liver-protective lifestyle intervention has not achieved NASH and fibrosis improvement goals
Liver-protective lifestyle modification is the established first-line approach in metabolic dysfunction-associated steatotic liver disease (MASLD). When this approach does not produce the weight loss and histological changes needed to resolve steatohepatitis or improve fibrosis, a structured next-line protocol is indicated.
Why the previous step was insufficient
The first-line programme — a liver-protective lifestyle intervention including a caloric-deficit diet, increased physical activity, and alcohol abstinence where clinically indicated — requires weight loss exceeding 10% to generally achieve improvement in NASH and hepatic fibrosis. When this threshold is not reached and steatohepatitis or significant fibrosis persists, escalation to the next step is considered.
Clinical goals of this protocol
The target outcomes for this next-line approach include resolution of NASH, improvement in hepatic fibrosis, and sustained weight loss of up to 30%.
Approach — partial overview
For appropriately selected patients who meet specific eligibility criteria, a metabolic surgical intervention may be considered — provided that certain hepatic contraindications are absent. The complete eligibility criteria, clinical decision pathway, and full management details are available in the structured protocol.
References
DOI: 10.1097/HEP.0000000000000323
- Bariatric surgery should be considered as a therapeutic option in patients who meet criteria for metabolic weight loss surgery, as it effectively resolves NAFLD or NASH in the majority of patients without cirrhosis and reduces mortality from CVD and malignancy.
- Although currently accepted criteria for bariatric surgery are BMI ≥ 40 kg/m2 irrespective of metabolic comorbid disease or BMI ≥ 35 kg/m2 with comorbidities (T2DM or pre-DM, uncontrolled hypertension, osteoarthritis of hip or knee, urinary incontinence), NAFLD/NASH is increasingly accepted as a comorbid condition benefitting from bariatric surgery.
- Decompensated cirrhosis should be considered an absolute contraindication for bariatric surgery due to increased risk and unproven liver-related benefit, unless performed in conjunction with liver transplantation at experienced centers.
- Bariatric surgery can resolve NASH, improve hepatic fibrosis, induce sustained weight loss of up to 30%, cure diabetes, and decrease all-cause morbidity and mortality.
View source ↗